Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Real-world experience with varnimcabtagene autoleucel (murine CD19 CAR-T) from India: A step towards enhanced patient access with excellent safety and efficacy

Blood (2025) 146 (Supplement 1): 6304.

https://doi.org/10.1182/blood-2025-6304

Published: 2025

Journal Articles

Germline mediated HR deficiency, alu element duplication, and immune pathway alterations define aggressive, drug-resistant multiple myeloma

Anindyajit Banerjee, Sombuddharoy Bhowmick, Smreti Vasudevan, Anurag Mehta, Narendra Agrawal, Vipul Sheth, Dr Dinesh Bhurani, Neeraj Arora, Jyotishankar Raychaudhuri

Blood (2025) 146 (Supplement 1): 7461.

https://doi.org/10.1182/blood-2025-7461

Published: 2025

Journal Articles

FLAG/VEN as a frontline induction therapy for AML: A multi-centre experience of Anthracycline free approach from India

Mohd Rizwan Shaikh, Mayank Soni Mayank Soni, Krishna Veni, Rashmi Chand, faran Naim, Rohan Halder, Narendra Agrawal, Vipul Sheth, Supriya Adak, Dinesh Bhurani, Rayaz Ahmed

Blood (2025) 146 (Supplement 1): 3407.

https://doi.org/10.1182/blood-2025-3407

Published: 2025

Journal Articles

Ulysses Road to Ithaca! MR4.5 at 24 Months Predicts Treatment Free Remission and Survival

Aakanksha Singh, Narendra Agrawal, Rayaz Ahmed, Dinesh Bhurani, Reema Singh, Jyotishankar Raychaudhuri

Blood (2024) 144 (Supplement 1): 6609.

https://doi.org/10.1182/blood-2024-210065

Published: 2024

Journal Articles

Response Adapted Dasatinib De-Escalation Strategy Compared to Upfront Low-Dose Dasatinib: A Prospective Cohort Study

Reema Singh, Sujay Rainchwar, Sakshi Bhatnagar, Nakul Tikare, Roy Palatty, Tribikram Panda, Rayaz Ahmed, Narendra Agrawal, Dinesh Bhurani, Rohan Halder

Blood (2024) 144 (Supplement 1): 3154.

https://doi.org/10.1182/blood-2024-206740

Published: 2024

Journal Articles

Talicabtagene Autoleucel (humanized CD19 CAR-T) As a Second Line Therapy in r/r B-Cell Lymphoma: Sub-Analysis from a Phase I/II Trial

Blood (2024) 144 (Supplement 1): 7203.

https://doi.org/10.1182/blood-2024-201984

Published: 2024

Journal Articles

CD 19 CAR T-Cell Therapy in R/R B Cell Malignancies : A Real World Experience from CAR T Working Group, Delhi Ncr ,India

Prashant Mehta, Pravas Mishra, Dinesh Bhurani, Vidit Kapoor, Esha Kaul, Rayaz Ahmed, Saphalta Baghmar, Swati Pabbi, Rahul Katharia, Nupur Das, Narendra Agrawal, Rohan Halder, Roy Palatty, Reema Singh, Faran Naim, Jagsahib Kaur

Blood (2024) 144 (Supplement 1): 7772.

https://doi.org/10.1182/blood-2024-205903

Published: 2024

Journal Articles

Prephase Rituximab Followed By Cladirabine in Newly Diagnosed Hairy Cell Leukaemia: A Tertiary Care Center Experience from North India

Tribikram Panda, Reema Singh, Rohan Halder, Roy Palatty, Nakul Tikare, Sakshi Bhatnagar, Rayaz Ahmed, Narendra Agrawal, Dinesh Bhurani

Blood (2024) 144 (Supplement 1): 6335.

https://doi.org/10.1182/blood-2024-204545

Published: 2024

Journal Articles

Gilteritinib for FLT3 Mutated r/r AML: Is the Reality Admirable?

Disha Disha, Aakanksha Singh, Rohan Halder, Roy Palatty, Narendra Agrawal, Tribikram Panda, Nakul Tikare, Rayaz Ahmed, Dinesh Bhurani

Blood (2024) 144 (Supplement 1): 5979.

https://doi.org/10.1182/blood-2024-208207

Published: 2024

Journal Articles

A Retrospective Comparative Analysis of Intensive Vs. Non-Intensive Chemotherapy in Treatment Naïve Acute Myeloid Leukemia (AML) Patients in India

Mohd Rizwan Mohamad Anwar Shaikh, Bhumika Singh, Reema Singh, Rohan Halder, Karuna Jha, Tribikram Panda, Rayaz Ahmed, Narendra Agrawal, Dinesh Bhurani

Blood (2023) 142 (Supplement 1): 5842.

https://doi.org/10.1182/blood-2023-188838

Published: 2023

Journal Articles

Risk and Response Adapted Approach for Treatment of Myeloma: Pushing Autologous Transplant Down the Hierarchy

Aakanksha Singh, Reema Singh, Rohan Halder, Karuna Jha, Tribikram Panda, Amir Khan Maroof, Niharika Bhatia, Rayaz Ahmed, Dinesh Bhurani, Narendra Agrawal

Blood (2023) 142 (Supplement 1): 3600.

https://doi.org/10.1182/blood-2023-186745

Published: 2023

Journal Articles

Casting Hope, Defying Odds: Unveiling the Impact of Haplo-Identical Stem Cell Transplant in Myeloid Malignancies - a Tertiary Cancer Care Center Experience

Reema Singh, Sujay Rainchwar, Rohan Halder, Niharika Bhatia, Karuna Jha, Tribikram Panda, Rayaz Ahmed, Dinesh Bhurani, Narendra Agrawal

Blood (2023) 142 (Supplement 1): 6983.

https://doi.org/10.1182/blood-2023-181474

Published: 2023

Journal Articles

Allogeneic Stem Cell Transplant for High-Risk Transfusion Dependent Thalassemia [Tdt] - a Comparative Analysis of Flu/Bu/Cy/ATG Versus Flu/Thio/Treo Regimen

Rohan Halder, Reshmi Harikumar Pillai, Vinayak Hemant Gupta, Sujay Rainchwar, Karuna Jha, Tribikram Panda, Rayaz Ahmed, Narendra Agrawal, Reema Singh, Dinesh Bhurani

Blood (2023) 142 (Supplement 1): 4961.

https://doi.org/10.1182/blood-2023-186817

Published: 2023

Journal Articles

Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)

Blood (2022) 140 (Supplement 1): 6096–6098.

https://doi.org/10.1182/blood-2022-167099

Published: 2022

Journal Articles

Effectiveness and Safety of Rituximab Biosimilar in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results from a Prospective, Multicentre, Real-World Registry Study

Blood (2022) 140 (Supplement 1): 12087–12088.

https://doi.org/10.1182/blood-2022-158455

Published: 2022

Journal Articles

Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience

Blood (2022) 140 (Supplement 1): 8127–8128.

https://doi.org/10.1182/blood-2022-165770

Published: 2022

Journal Articles

An Observational Prospective Study of Dasatinib 50mg Daily As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia Patients in Chronic Phase

Reema Singh, Rohan Halder, Jyotsna Kapoor, Megha Verma, Pallavi Mehta, Narendra Agrawal, Rayaz Ahmed, Dinesh Bhurani

Blood (2022) 140 (Supplement 1): 12197–12199.

https://doi.org/10.1182/blood-2022-158453

Published: 2022

Journal Articles

Retrospective Study of Treatment Free Remission in Patients with Chronic Myeloid Leukaemia(CML) Treated at Tertiary Care Oncology Centre from India

Megha Verma, Rohan Halder, Reema Singh, Pallavi Mehta, Narendra Agrawal, Rayaz Ahmed, Dinesh Bhurani

Blood (2022) 140 (Supplement 1): 12222.

https://doi.org/10.1182/blood-2022-168574

Published: 2022

Journal Articles

Maintenance with Hypomethylating Agents Post-Transplant in Acute Myeloid Leukemia Patients: Safe and Affordable Way to Induce Graft Versus Leukemia Effect

Sujay Rainchwar, Pallavi Mehta, Rayaz Ahmed, Narendra Agrawal, Pritish Chandra Patra

Blood (2022) 140 (Supplement 1): 12902–12903.

https://doi.org/10.1182/blood-2022-164568

Published: 2022

Journal Articles

Hypomethylating Agent Maintenance for Favorable and Intermediate Risk Acute Myeloid Leukemia

Reema Singh, Rohan Halder, Megha Verma, Pallavi Mehta, Narendra Agrawal, Rayaz Ahmed, Dinesh Bhurani

Blood (2022) 140 (Supplement 1): 11713–11715.

https://doi.org/10.1182/blood-2022-162124

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Real-world experience with varnimcabtagene autoleucel (murine CD19 CAR-T) from India: A step towards enhanced patient access with excellent safety and efficacy

Germline mediated HR deficiency, alu element duplication, and immune pathway alterations define aggressive, drug-resistant multiple myeloma

FLAG/VEN as a frontline induction therapy for AML: A multi-centre experience of Anthracycline free approach from India

Ulysses Road to Ithaca! MR4.5 at 24 Months Predicts Treatment Free Remission and Survival

Response Adapted Dasatinib De-Escalation Strategy Compared to Upfront Low-Dose Dasatinib: A Prospective Cohort Study

Talicabtagene Autoleucel (humanized CD19 CAR-T) As a Second Line Therapy in r/r B-Cell Lymphoma: Sub-Analysis from a Phase I/II Trial

CD 19 CAR T-Cell Therapy in R/R B Cell Malignancies : A Real World Experience from CAR T Working Group, Delhi Ncr ,India

Prephase Rituximab Followed By Cladirabine in Newly Diagnosed Hairy Cell Leukaemia: A Tertiary Care Center Experience from North India

Gilteritinib for FLT3 Mutated r/r AML: Is the Reality Admirable?

A Retrospective Comparative Analysis of Intensive Vs. Non-Intensive Chemotherapy in Treatment Naïve Acute Myeloid Leukemia (AML) Patients in India

Risk and Response Adapted Approach for Treatment of Myeloma: Pushing Autologous Transplant Down the Hierarchy

Casting Hope, Defying Odds: Unveiling the Impact of Haplo-Identical Stem Cell Transplant in Myeloid Malignancies - a Tertiary Cancer Care Center Experience

Allogeneic Stem Cell Transplant for High-Risk Transfusion Dependent Thalassemia [Tdt] - a Comparative Analysis of Flu/Bu/Cy/ATG Versus Flu/Thio/Treo Regimen

Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)

Effectiveness and Safety of Rituximab Biosimilar in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results from a Prospective, Multicentre, Real-World Registry Study

Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience

An Observational Prospective Study of Dasatinib 50mg Daily As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia Patients in Chronic Phase

Retrospective Study of Treatment Free Remission in Patients with Chronic Myeloid Leukaemia(CML) Treated at Tertiary Care Oncology Centre from India

Maintenance with Hypomethylating Agents Post-Transplant in Acute Myeloid Leukemia Patients: Safe and Affordable Way to Induce Graft Versus Leukemia Effect

Hypomethylating Agent Maintenance for Favorable and Intermediate Risk Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only